Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024279044> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2024279044 endingPage "213" @default.
- W2024279044 startingPage "210" @default.
- W2024279044 abstract "<b><i>Objectives:</i></b> We conducted a phase II clinical trial of high-dose cetuximab plus irinotecan in KRAS wild-type patients who progressed on standard-dose cetuximab plus irinotecan. <b><i>Methods:</i></b> Patients who progressed within 4 weeks from receiving a minimum of 6 weeks of standard-dose cetuximab plus irinotecan were included in this study. Cetuximab was administered at 500 mg/m<sup>2</sup>/week and irinotecan was administered at the same dose/schedule on which each individual patient had previously progressed. The study was closed early after having met its primary end point. <b><i>Results:</i></b> Twenty patients were treated. The regimen was found to be efficacious, with 9 patients achieving disease control lasting more than 12 weeks. The median progression-free survival and overall survival were 2.8 and 6.6 months, respectively. The toxicity profile was favorable, with the exception of grade 3–4 hypomagnesemia which was noted in 25% of patients. <b><i>Conclusions:</i></b> High-dose cetuximab plus irinotecan rechallenge can re-elicit clinical benefits in patients who have previously failed cetuximab plus irinotecan treatment. The clinical benefits are modest and may be related to cetuximab rechallenge rather than cetuximab dose escalation." @default.
- W2024279044 created "2016-06-24" @default.
- W2024279044 creator A5000500580 @default.
- W2024279044 creator A5001951661 @default.
- W2024279044 creator A5011459161 @default.
- W2024279044 creator A5025469479 @default.
- W2024279044 creator A5037345000 @default.
- W2024279044 creator A5047907725 @default.
- W2024279044 creator A5055566735 @default.
- W2024279044 date "2013-01-01" @default.
- W2024279044 modified "2023-10-16" @default.
- W2024279044 title "A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan" @default.
- W2024279044 cites W2019607817 @default.
- W2024279044 cites W2074269835 @default.
- W2024279044 cites W2095201384 @default.
- W2024279044 cites W2107692859 @default.
- W2024279044 cites W2131371081 @default.
- W2024279044 cites W2156700619 @default.
- W2024279044 cites W2156834559 @default.
- W2024279044 cites W4289258260 @default.
- W2024279044 cites W2115790682 @default.
- W2024279044 doi "https://doi.org/10.1159/000346328" @default.
- W2024279044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23328486" @default.
- W2024279044 hasPublicationYear "2013" @default.
- W2024279044 type Work @default.
- W2024279044 sameAs 2024279044 @default.
- W2024279044 citedByCount "10" @default.
- W2024279044 countsByYear W20242790442014 @default.
- W2024279044 countsByYear W20242790442015 @default.
- W2024279044 countsByYear W20242790442016 @default.
- W2024279044 countsByYear W20242790442018 @default.
- W2024279044 countsByYear W20242790442019 @default.
- W2024279044 countsByYear W20242790442020 @default.
- W2024279044 crossrefType "journal-article" @default.
- W2024279044 hasAuthorship W2024279044A5000500580 @default.
- W2024279044 hasAuthorship W2024279044A5001951661 @default.
- W2024279044 hasAuthorship W2024279044A5011459161 @default.
- W2024279044 hasAuthorship W2024279044A5025469479 @default.
- W2024279044 hasAuthorship W2024279044A5037345000 @default.
- W2024279044 hasAuthorship W2024279044A5047907725 @default.
- W2024279044 hasAuthorship W2024279044A5055566735 @default.
- W2024279044 hasConcept C121608353 @default.
- W2024279044 hasConcept C126322002 @default.
- W2024279044 hasConcept C143998085 @default.
- W2024279044 hasConcept C2779998722 @default.
- W2024279044 hasConcept C2780259306 @default.
- W2024279044 hasConcept C2781187634 @default.
- W2024279044 hasConcept C2781413609 @default.
- W2024279044 hasConcept C526805850 @default.
- W2024279044 hasConcept C71924100 @default.
- W2024279044 hasConcept C90924648 @default.
- W2024279044 hasConceptScore W2024279044C121608353 @default.
- W2024279044 hasConceptScore W2024279044C126322002 @default.
- W2024279044 hasConceptScore W2024279044C143998085 @default.
- W2024279044 hasConceptScore W2024279044C2779998722 @default.
- W2024279044 hasConceptScore W2024279044C2780259306 @default.
- W2024279044 hasConceptScore W2024279044C2781187634 @default.
- W2024279044 hasConceptScore W2024279044C2781413609 @default.
- W2024279044 hasConceptScore W2024279044C526805850 @default.
- W2024279044 hasConceptScore W2024279044C71924100 @default.
- W2024279044 hasConceptScore W2024279044C90924648 @default.
- W2024279044 hasIssue "4" @default.
- W2024279044 hasLocation W20242790441 @default.
- W2024279044 hasLocation W20242790442 @default.
- W2024279044 hasOpenAccess W2024279044 @default.
- W2024279044 hasPrimaryLocation W20242790441 @default.
- W2024279044 hasRelatedWork W1963973664 @default.
- W2024279044 hasRelatedWork W2010163599 @default.
- W2024279044 hasRelatedWork W2120490763 @default.
- W2024279044 hasRelatedWork W2158346116 @default.
- W2024279044 hasRelatedWork W2262819074 @default.
- W2024279044 hasRelatedWork W2435704186 @default.
- W2024279044 hasRelatedWork W2617055067 @default.
- W2024279044 hasRelatedWork W2754584868 @default.
- W2024279044 hasRelatedWork W2984714837 @default.
- W2024279044 hasRelatedWork W3000288349 @default.
- W2024279044 hasVolume "84" @default.
- W2024279044 isParatext "false" @default.
- W2024279044 isRetracted "false" @default.
- W2024279044 magId "2024279044" @default.
- W2024279044 workType "article" @default.